Eisai China, Inc. (ECI), the wholly owned China subsidiary of Japan pharma Eisai Co., will repack and sell Alpha-Lipon 300 STADA®, an alpha-lipoic acid. Alpha-Lipon 300 STADA is a treatment for diabetic neuropathic pain developed by STADA Arzneimittel AG and currently sold through the company’s sales subsidiary Health Vision Enterprise Ltd. Available in China since 2005, Alpha-Lipon 300 STADA treats diabetic neuropathic pain through an antioxidant effect, which reduces overproduction of oxygen and normalizes glucose metabolism. More details...